Vasopressin receptor · PROTEIN FAMILY · Homo sapiens
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Move to another high-traffic target or paste a specific ChEMBL target ID.
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-14Vasopressin receptor shows approved-linked disease relevance led by diabetes insipidus. 5 more disease programs remain visible in the same review block. 2 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt P30518. Start with diabetes insipidus, then reuse UniProt P30518 as the stable protein anchor across project notes and exports.
Start with diabetes insipidus, then reuse UniProt P30518 as the stable protein anchor across project notes and exports.
Vasopressin receptor shows approved-linked disease relevance led by diabetes insipidus. 5 more disease programs remain visible in the same review block. 2 linked drugs remain visible in the same block.
Start review with diabetes insipidus because it currently carries approved-linked support. Linked drugs include DESMOPRESSIN ACETATE, VASOPRESSIN. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxyVasopressin V2 receptor
Review this target as Vasopressin receptor, mapped to UniProt P30518. ChEMBL maps the protein component as Vasopressin V2 receptor. Sequence length is 371 aa.
Protein source · UniProt accession via ChEMBL component mappingKeep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Vasopressin receptor as ChEMBL target CHEMBL2363078, mapped to UniProt P30518. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether Vasopressin receptor is the right protein anchor across sources, using UniProt P30518 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why diabetes insipidus is currently framed as approved-linked support. It currently carries 2 linked drugs in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardVerify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | Vasopressin receptor |
| Target Type | PROTEIN FAMILY |
| Organism | Homo sapiens |
| UniProt | P30518 |
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | Vasopressin V2 receptor |
| UniProt Accession | P30518 |
| Component Type | Protein |
| Sequence Length | 371 aa |
Vasopressin V2 receptor
Review this target as Vasopressin receptor, mapped to UniProt P30518. ChEMBL maps the protein component as Vasopressin V2 receptor. Sequence length is 371 aa.
Open Targets-ready disease context using the current target-indication evidence contract.
Vasopressin receptor shows approved-linked disease relevance led by diabetes insipidus. 5 more disease programs remain visible in the same review block.
Start review with diabetes insipidus because it currently carries approved-linked support. Linked drugs include DESMOPRESSIN ACETATE, VASOPRESSIN. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.